Navigation Links
GEN reports growing focus on PI3-kinase pathway in cancer research
Date:12/4/2008

New Rochelle, NY, December 4, 2008Researchers are taking a closer look at the phosphoinositide 3-kinase (PI3-kinase) pathway as studies continue to demonstrate that inhibiting this biological route suppresses tumor growth, reports Genetic Engineering & Biotechnology News (GEN). The pathway is involved in angiogenesis, cell growth, differentiation, and survival. In addition, it is part of the PI3/AKT/mTOR pathway, which plays a key role in cancer, according to the December issue of GEN (www.genengnews.com).

"The good news about cancer is that a report last month from the National Cancer Institute indicated that there is a decline in both cancer incidence and death rates in the U.S.," says John Sterling, Editor in Chief of GEN. "But the American Cancer Society estimates that there will still be over half a million cancer deaths in America in 2008 so novel therapies remain critical."

Exelixis, for example, has developed several potential cancer compounds, two of which (XL147 and XL765) target the PI3-kinase pathway. Company scientists say they are studying the pathway because there are a number of feedback loops that emanate from m-TOR and downstream kinases that circle back to the top of the pathway and turn on AKT, an enzyme that drives tumor survival signals.

Investigators at the University of London are exploring the role of PI3-kinase isoforms in normal physiology and disease. A team led by Dr. Bart Vanhaesebroeck isolated the PI3-kinase genes in various mammals and developed models to better understand gene function.

Also covered in the GEN article is research taking place at Eli Lilly, the Multiple Myeloma Research Foundation, Semafore Pharmaceuticals, Calistoga Pharmaceuticals, and Harvard Medical School.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1

Related biology news :

1. BIO-key Reports Second Quarter 2007 Results
2. Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results
3. Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia
4. BIO-key Reports Third Quarter 2007 Results
5. WHRC releases 4 key reports
6. Rong Li Lab reports protein interactions of MAP kinase signaling pathway
7. UVA reports surprising findings related to myotonic muscular dystrophy
8. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
9. MIT reports new twist in microRNA biology
10. Aware, Inc. Reports Fourth Quarter and 2007 Financial Results
11. Genetic Engineering & Biotechnology News reports on advances in miRNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
Breaking Biology Technology: